Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.47B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
EBITDA Margin
16.46%
TTM Avg
14.25%
3Y Avg
12.03%
5Y Avg
12.13%
Market Cap
$1.45B
EBITDA Margin
3.56%
TTM Avg
3.76%
3Y Avg
3.79%
5Y Avg
3.46%
Market Cap
$1.45B
EBITDA Margin
36.35%
TTM Avg
36.35%
3Y Avg
36.35%
5Y Avg
36.35%
Market Cap
$1.43B
EBITDA Margin
-74.29%
TTM Avg
-81.81%
3Y Avg
-115.58%
5Y Avg
-114.07%
Market Cap
$1.51B
EBITDA Margin
5.15%
TTM Avg
0.72%
3Y Avg
-7.50%
5Y Avg
-11313.48%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.47B | N/A | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 16.46% | 14.25% | 12.03% | 12.13% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 3.56% | 3.76% | 3.79% | 3.46% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 36.35% | 36.35% | 36.35% | 36.35% |
| Certara, Inc. (CERT)vs › | $1.45B | 18.52% | 17.87% | 16.34% | 15.57% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | -74.29% | -81.81% | -115.58% | -114.07% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 5.15% | 0.72% | -7.50% | -11313.48% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 21.45% | -50.92% | -538.26% | -378.46% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
